Sign In
Buy ENTX
$1.22
-0.0300 (-2.40%)
At Close: Jun 03, 2026
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
08:00am, Wednesday, 04'th Feb 2026
This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
08:30am, Wednesday, 21'st Jan 2026
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 202
FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613
Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections Novel PTH analog achieves susta
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference
08:00am, Tuesday, 18'th Nov 2025
JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies, today an
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
04:05pm, Friday, 14'th Nov 2025
FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Imp
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613's efficacy in both young postmenopausal women and in women 10 years post-menopause
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
08:45am, Thursday, 16'th Oct 2025
First-time presentation examining bone outcomes in early postmenopausal women First-time presentation examining bone outcomes in early postmenopausal women
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
09:45am, Thursday, 18'th Sep 2025
ENTX posts positive PK data for its first oral GLP-2 therapy, signaling a potential breakthrough in short bowel syndrome treatment.
Entera Bio Beats Q2 EPS Estimates
05:17pm, Friday, 08'th Aug 2025
Entera Bio (ENTX 1.11%), a clinical-stage biotech specializing in oral delivery of protein and peptide drugs, released its earnings for the second quarter of fiscal 2025 on August 8, 2025. The most no
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
04:05pm, Friday, 08'th Aug 2025
JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key bus
JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
04:05pm, Friday, 09'th May 2025
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key busi
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
04:05pm, Friday, 28'th Mar 2025
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therap
